More rules of the road can be found over at the CareFirst provider portal (CareFirst BlueCross BlueShield)
OZEMPIC mimics the action of human incretin hormones, stimulating insulin secretion and reducing glucagon in a glucose-dependent manner
Wellberg is also speaking to her fellow scientists through the review article
Key points Obesity is a risk factor for developing osteoarthritis (OA), gout, rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), and is associated with higher disease activity and/or severity, and worse response to common treatments
dosage, titration schedule, and treatment duration must be determined based on a formal research protocol
BMI of 30 or higher qualifies outright